GSK plc
GLAXF
$19.36
$0.0050.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.93% | 1.08% | 10.69% | 10.62% | 15.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.93% | 1.08% | 10.69% | 10.62% | 15.45% |
| Cost of Revenue | 11.87% | 6.67% | 9.43% | 5.09% | -7.98% |
| Gross Profit | 0.68% | -1.05% | 11.15% | 12.70% | 28.88% |
| SG&A Expenses | 3.65% | 75.03% | 6.67% | 0.08% | 14.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 130.93% | 62.32% | 32.81% | 12.40% | -128.67% |
| Total Operating Expenses | 15.58% | 40.27% | 10.38% | 6.26% | 3.64% |
| Operating Income | -39.57% | -75.21% | 11.50% | 22.02% | 101.01% |
| Income Before Tax | 53.15% | -96.33% | -24.17% | -25.80% | -75.35% |
| Income Tax Expenses | 436.43% | -100.40% | -20.46% | 3.67% | -2,109.48% |
| Earnings from Continuing Operations | 29.78% | -95.64% | -24.69% | -30.79% | -74.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -86.87% | -80.60% | -9.11% | 74.08% | 59.39% |
| Net Income | 21.95% | -104.07% | -27.21% | -26.69% | -75.24% |
| EBIT | -39.57% | -75.21% | 11.50% | 22.02% | 101.01% |
| EBITDA | -18.37% | -50.27% | 17.21% | 13.92% | 52.78% |
| EPS Basic | 21.18% | -104.05% | -27.67% | -27.13% | -75.37% |
| Normalized Basic EPS | -48.54% | -85.83% | 12.18% | 39.99% | 234.07% |
| EPS Diluted | 20.94% | -104.10% | -27.65% | -27.32% | -75.19% |
| Normalized Diluted EPS | -48.59% | -85.84% | 12.10% | 39.94% | 234.08% |
| Average Basic Shares Outstanding | 0.62% | 0.62% | 0.64% | 0.62% | 0.55% |
| Average Diluted Shares Outstanding | 0.70% | 0.71% | 0.71% | 0.69% | 0.61% |
| Dividend Per Share | 3.12% | 10.10% | 7.99% | 11.88% | 23.03% |
| Payout Ratio | -0.09% | -28.24% | 0.62% | 0.46% | 2.71% |
